A new molecule offers hope for the development of new analgesics for bone pain.
Philippe Sarret is Professor at the Université de Sherbrooke, Scientific Director of the Sherbrooke Pharmacology Institute (SPI), former Director and member of the QPRN, and may well have paved the way for better management of bone pain. Prof. Sarret and his team have developed a molecule that specifically targets the receptor involved in the development of bone pain. This molecule, known as pepducin, has shown positive effects in reducing pain in vitro and in vivo, and could pave the way for the development of new analgesic molecules. It has also been the subject of a recent scientific publication. This discovery is significant given that bone pain is a phenomenon affecting a large proportion of women with metastatic cancer.
